Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.42 |
| ▸ | CA1 | P00915 | 12/20 | 0.42 |
| ▸ | CA12 | O43570 | 10/20 | 0.42 |
| ▸ | CA9 | Q16790 | 10/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | GRK2 | P25098 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4799004 | 0.87 | TGM2 (0.38) | CA2CA1CA12CA9CTSL | |
| SCHEMBL4797902 | 0.84 | PARP1 (0.41) | GRK2MEN1KMT2A | |
| SCHEMBL6685731 | 0.77 | CA1 (0.41) | CA2CA1CA12CA9CTSL | |
| SCHEMBL4798248 | 0.76 | CTSL (0.46) | CA2CA1CA12CA9CTSL | |
| SCHEMBL4800097 | 0.75 | CTSK (0.42) | CTSLCTSSCTSKLMNAPKM | |
| SCHEMBL4798680 | 0.73 | CTSS (0.48) | CTSLCTSSCTSK | |
| SCHEMBL4798876 | 0.73 | ALDH1A1 (0.39) | CTSLCTSSCTSKRAB9AMEN1 | |
| SCHEMBL4800960 | 0.71 | CTSL (0.47) | CA2CA1CA12CA9CTSL | |
| SCHEMBL6689442 | 0.70 | CTSL (0.52) | CA2CA1CA12CA9CTSL | |
| SCHEMBL4800967 | 0.69 | CTSL (0.61) | CA2CA1CA12CA9CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | claimed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | disclosed |
| US-7384970-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-06-10 | — | — | US | disclosed |
| US-20040248887-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-12-09 | — | — | US | disclosed |
| WO-2004084843-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248887-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | CA2 321/4885CA1 317/4885CA12 535/4885 |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CA2 321/4885CA1 317/4885CA12 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.